Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclophosphamide + epirubicin + pertuzumab + trastuzumab
- Development stage
- Unknown
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Subcutaneous
01
Overview
A combination chemotherapy and targeted therapy regimen used primarily for the treatment of HER2-positive breast cancer. This regimen combines two chemotherapy agents (cyclophosphamide and epirubicin) with two HER2-targeted monoclonal antibodies (pertuzumab and trastuzumab). The dual HER2 blockade provided by pertuzumab and trastuzumab works synergistically, with each antibody binding to different domains of the HER2 receptor. This combination is typically used in neoadjuvant (pre-surgical) settings for early-stage or locally advanced HER2-positive breast cancer.
02
Targets
TOP2A (DNA topoisomerase II)ERBB2 (Erb-b2 receptor tyrosine kinase 2)DNA
Beyond the preview
Go deeper on cyclophosphamide + epirubicin + pertuzumab + trastuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclophosphamide + epirubicin + pertuzumab + trastuzumab.